FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4280491846> ?p ?o ?g. }

• W4280491846 endingPage "1020.e3" @default.
• W4280491846 startingPage "1012" @default.
• W4280491846 abstract "Objective Extended anticoagulation therapy should always be considered after standard treatment of an unprovoked episode of venous thromboembolism (VTE). It can also be considered for selected patients with provoked VTE. However, the evidence-based protocols suggested by some clinical guidelines and risk assessment tools to guide this practice are limited and ambiguous. The goal of the present survey research was to analyze current practices in applying extended anticoagulation therapy for patients with VTE among members of the American Venous Forum (AVF) and European Venous Forum (EVF). Methods An online survey was created by the AVF Research Committee. The survey consisted of 16 questions to identify the country of practice, specialty, experience of the participating physicians, and their clinical practice patterns in applying extended anticoagulation therapy for VTE patients. The survey was distributed via e-mail to the members of the AVF and EVF. Results A total of 144 practitioners, 48 AVF members (33%) and 96 EVF members (66%), participated in the survey. Most of the respondents identified themselves as vascular specialists with primary certification in vascular surgery (70%), vascular medicine or angiology (9%), and venous disease or phlebology (3%). Of the 144 respondents, 72% believed that the risk of VTE recurrence will generally overweigh the risk of bleeding for patients with unprovoked VTE. Extended anticoagulation therapy might be used by 97% of providers. Different patterns in real world clinical practice were identified. More than one half of the practitioners estimated the VTE recurrence and bleeding risk subjectively. The antithrombotic drugs most commonly used for secondary prophylaxis were rivaroxaban, apixaban, warfarin, dabigatran, and aspirin, in decreasing order of frequency. Among the reasons selected for not regularly considering extended anticoagulation therapy were the lack of specific clinical practice guidelines (24%), lack of reported evidence (9%), and absence of valid VTE and/or bleeding risk prediction calculators (8%). Twelve participants (8%) stated that extended anticoagulation therapy would not be beneficial for most patients with VTE. Ten participants (7%) indicated that prescribing extended anticoagulation therapy was outside the scope of their specialty. Conclusions Different practice patterns exist regarding extending anticoagulation therapy beyond the standard treatment for patients with VTE. Major gaps in knowledge remain a serious challenge at least partially explaining the inaccuracy and inconsistency in long-term VTE management. Appropriately designed studies are needed to evaluate risk stratification tools when contemporary best medical therapy is used, accurately predict VTE recurrence and its long-term outcomes, and tailor safe and effective secondary prophylaxis." @default.
• W4280491846 created "2022-05-22" @default.
• W4280491846 creator A5004436654 @default.
• W4280491846 creator A5005792761 @default.
• W4280491846 creator A5027151045 @default.
• W4280491846 creator A5033014380 @default.
• W4280491846 creator A5035826935 @default.
• W4280491846 creator A5040704848 @default.
• W4280491846 creator A5048850165 @default.
• W4280491846 creator A5050192237 @default.
• W4280491846 creator A5061702412 @default.
• W4280491846 creator A5068331686 @default.
• W4280491846 creator A5069989827 @default.
• W4280491846 creator A5071744828 @default.
• W4280491846 creator A5075432052 @default.
• W4280491846 creator A5085702050 @default.
• W4280491846 creator A5091376707 @default.
• W4280491846 date "2022-09-01" @default.
• W4280491846 modified "2023-09-27" @default.
• W4280491846 title "Extended anticoagulation for venous thromboembolism: A survey of the American Venous Forum and the European Venous Forum" @default.
• W4280491846 cites W1508825876 @default.
• W4280491846 cites W1521441456 @default.
• W4280491846 cites W1524501969 @default.
• W4280491846 cites W1830075536 @default.
• W4280491846 cites W1847159932 @default.
• W4280491846 cites W1964644585 @default.
• W4280491846 cites W1978280229 @default.
• W4280491846 cites W1991787472 @default.
• W4280491846 cites W1997534178 @default.
• W4280491846 cites W2003601153 @default.
• W4280491846 cites W2005086258 @default.
• W4280491846 cites W2007680892 @default.
• W4280491846 cites W2013710547 @default.
• W4280491846 cites W2022713742 @default.
• W4280491846 cites W2029581583 @default.
• W4280491846 cites W2046219226 @default.
• W4280491846 cites W2059305858 @default.
• W4280491846 cites W2067741035 @default.
• W4280491846 cites W2071111754 @default.
• W4280491846 cites W2074708727 @default.
• W4280491846 cites W2082378560 @default.
• W4280491846 cites W2087002320 @default.
• W4280491846 cites W2092668085 @default.
• W4280491846 cites W2112378432 @default.
• W4280491846 cites W2112681385 @default.
• W4280491846 cites W2113530759 @default.
• W4280491846 cites W2119221555 @default.
• W4280491846 cites W2127985968 @default.
• W4280491846 cites W2130199362 @default.
• W4280491846 cites W2139785591 @default.
• W4280491846 cites W2162398328 @default.
• W4280491846 cites W2171381436 @default.
• W4280491846 cites W2225937646 @default.
• W4280491846 cites W2294236942 @default.
• W4280491846 cites W2528331098 @default.
• W4280491846 cites W2568332688 @default.
• W4280491846 cites W2583457043 @default.
• W4280491846 cites W2595086780 @default.
• W4280491846 cites W2595581694 @default.
• W4280491846 cites W2622667479 @default.
• W4280491846 cites W2771956980 @default.
• W4280491846 cites W2810340659 @default.
• W4280491846 cites W2887430390 @default.
• W4280491846 cites W2964299611 @default.
• W4280491846 cites W3026637204 @default.
• W4280491846 cites W3090209681 @default.
• W4280491846 cites W3112865739 @default.
• W4280491846 cites W3121421862 @default.
• W4280491846 doi "https://doi.org/10.1016/j.jvsv.2022.03.013" @default.
• W4280491846 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35561974" @default.
• W4280491846 hasPublicationYear "2022" @default.
• W4280491846 type Work @default.
• W4280491846 citedByCount "1" @default.
• W4280491846 countsByYear W42804918462023 @default.
• W4280491846 crossrefType "journal-article" @default.
• W4280491846 hasAuthorship W4280491846A5004436654 @default.
• W4280491846 hasAuthorship W4280491846A5005792761 @default.
• W4280491846 hasAuthorship W4280491846A5027151045 @default.
• W4280491846 hasAuthorship W4280491846A5033014380 @default.
• W4280491846 hasAuthorship W4280491846A5035826935 @default.
• W4280491846 hasAuthorship W4280491846A5040704848 @default.
• W4280491846 hasAuthorship W4280491846A5048850165 @default.
• W4280491846 hasAuthorship W4280491846A5050192237 @default.
• W4280491846 hasAuthorship W4280491846A5061702412 @default.
• W4280491846 hasAuthorship W4280491846A5068331686 @default.
• W4280491846 hasAuthorship W4280491846A5069989827 @default.
• W4280491846 hasAuthorship W4280491846A5071744828 @default.
• W4280491846 hasAuthorship W4280491846A5075432052 @default.
• W4280491846 hasAuthorship W4280491846A5085702050 @default.
• W4280491846 hasAuthorship W4280491846A5091376707 @default.
• W4280491846 hasConcept C126322002 @default.
• W4280491846 hasConcept C177713679 @default.
• W4280491846 hasConcept C20387591 @default.
• W4280491846 hasConcept C2777015399 @default.
• W4280491846 hasConcept C2779974597 @default.
• W4280491846 hasConcept C2780868729 @default.
• W4280491846 hasConcept C2991741193 @default.
• W4280491846 hasConcept C512399662 @default.

• next